Table 8: Rate of Secondary Amputation and Frequency of Adverse Events.

	Amputation N (%)	Adverse Events N (%)
Blume et al. 2008 (4)	Secondary amputation NPWT: 7 (4.1) Control: 17 (10.2) P = 0.035 Note: 2 in NPWT and 13 in control were minor amputations	At 6 months Wound infection NPWT: 4 (2.4) CL: 1 (0.6) P = .37 Osteomyelitis NPWT: 1 (0.6) CL: 0 (0) Staphylococus infection NPWT: 1 (0.6) CL: 0 (0) Infected skin ulcer NPWT: 1 (0.6) CL: 2 (1.2) P = .6 Edema NPWT: 5 (3) Control: 7 (4.2) P = .57 Cellulitis NPWT: 4 (2.4) Control: 1 (0.6) P = .37
Armstrong et al. 2005 (6)	Second amputation NPWT: 2 (3) Control: 9 (11) P = .06 RR, 0.225 (95% CI 0.05-1.1) High level (below or above knee) amputation: NPWT: 0 Control: 5 (2 above knee) P = .06	Treatment-related adverse events NPWT: 9 (12); 1 was serious CL: 11 (13); 5 were serious Mean duration of treatment-related adverse events NPWT: 18 days (SD 22.3) Control: 24.3 days (SD 34.5) Wound infection NPWT: 13 (17); Not related to NPWT CL: 5 (6); 2 related to treatment
Vuerstaek et al. 2006 (7)	None	Wound infection NPWT: 0 CL: 1 Not significant Cutaneous damage secondary to therapy NPWT: 7 CL:2 P < .05 Pain NPWT: 3 CL: 1 Not significant Other Erysipelas: 1 in NPWT Bleeding at donor site: 2 in CL
Llanos et al. 2006 (5)	None	NR

NPWT, Negative pressure wound therapy; NR, Not reported